BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease
BMO Capital Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $37
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
Express News | BridgeBio Pharma Inc - Topline Data Readout From Interim Analysis Expected in 2025
Express News | BridgeBio Completes Enrollment of Fortify, Phase 3 Registrational Study of Bbp-418 in Limb-Girdle Muscular Dystrophy Type 2I/R9 (Lgmd2I/R9)
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $43
Buy Recommendation for BridgeBio Pharma Amidst Promising Drug Trials and Upcoming FDA Decision
Reported Earlier, BridgeBio's Acoramidis Shows 42% Reduction in Mortality and Heart Hospitalizations in ATTR-CM Study, New Drug Application Under FDA Review
Express News | BridgeBio: Attribute-Cm Study Shows 42% Cut in Composite ACM and Recurrent Cvh Events at 30 Months Observed With Acoramidis Treatment Vs Placebo
BMO Capital Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $37
BMO Capital analyst Kostas Biliouris maintains $BridgeBio Pharma(BBIO.US)$ with a hold rating, and maintains the target price at $37.According to TipRanks data, the analyst has a success rate of 40.6%
Sector Update: Health Care Stocks Steady Premarket Tuesday
BridgeBio Gets FDA Breakthrough Therapy Designation for Achondroplasia Treatment
Express News | BridgeBio Pharma Inc - Propel 3 Phase 3 Study Enrollment to Complete by Year-End
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
Cantor Fitzgerald Reiterates Overweight on BridgeBio Pharma, Maintains $70 Price Target
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $43
H.C. Wainwright analyst Ram Selvaraju maintains $BridgeBio Pharma(BBIO.US)$ with a buy rating, and maintains the target price at $43.According to TipRanks data, the analyst has a success rate of 42.6%
BridgeBio Pharma Price Target Maintained With a $43.00/Share by HC Wainwright & Co.
BridgeBio Pharma Analyst Ratings
Form 144 | BridgeBio Pharma(BBIO.US) Insider Proposes to Sell 156.31 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Sep 13, $BridgeBio Pharma(BBIO.US)$ Insider KKR Genetic Disorder L.P. intends to sell 5.8 million shares of its common stock on Sep 13, with a total market value of
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ